Introduction
============

Congenital melanocytic nevus (CMN) syndrome (formerly known as neurocutaneous melanosis) is the involvement of typically large pigmented melanocytic nevi with extra-cutaneous features, such as certain facial characteristics and melanotic cells within the central nervous system (CNS; [@bib2]; [@bib19]; [@bib16]). Pigmented hairy nevi can cover up to 80% of the body surface area, and neurological abnormalities can lead to intractable seizures and neurodevelopmental delay. There is also a significant risk of primary melanoma within the skin, brain, or leptomeninges ([@bib22]; [@bib18]). Previous work has shown that CMN syndrome is caused, in roughly 80% of cases, by a single post-zygotic mutation of *NRAS* codon 61 in a neuro-ectodermal precursor ([@bib21]). However, some familial pre-disposition also suggests a germ-line contribution to the development of CMN ([@bib6]; [@bib18]; [@bib7]). There is currently no treatment for this condition, and where melanoma develops the outcome is almost universally fatal. Despite recent advances in treatment of some types of melanoma with targeted therapies, a cure for melanoma harboring *NRAS* mutation remains particularly elusive ([@bib36]). Therefore, a potential treatment for the cutaneous and extra-cutaneous features of CMN syndrome is most likely prior to its acquisition of additional genetic alterations *en route* to melanoma.

In both CMN and acquired melanocytic nevi, nevus cells are thought to be maintained in a proliferation arrested state by cellular senescence ([@bib24]; [@bib12]; [@bib39]), a tumor-suppressive, stable proliferation arrest triggered by activated oncogenes and other molecular stresses ([@bib32]). A complex network of effectors enacts the senescence response, including DNA damage signaling, activation of the pRB and p53 pathways and, notably, repression of Wnt signaling ([@bib42]; [@bib27]; [@bib14]; [@bib32]). Paradoxically, however, we and others have shown that nevus melanocytes, including in CMN, often exhibit markers of activated Wnt signaling ([@bib4]; [@bib15]; [@bib30]; [@bib17]; [@bib27]), and activated Wnt signaling is able to bypass or delay senescence in mouse models ([@bib8]; [@bib27]; [@bib14]). We therefore reasoned that activated Wnt signaling, in addition to the *NRAS* mutation, might influence the varied phenotype of CMN syndrome.

Results
=======

Altered Wnt signaling in human CMN syndrome
-------------------------------------------

To more directly assess the status of Wnt signaling in human CMN, we stained such nevi for markers of activated Wnt signaling. As shown previously ([@bib17]), CMN expressed nuclear and cytoplasmic localized β-catenin. In addition, these nevi consistently expressed cyclin D1 and c-MYC ([Figure 1](#fig1){ref-type="fig"}) indicative of activated Wnt signaling and in contrast to normal epidermal melanocytes that do not express nuclear cyclin D1 and c-myc ([@bib27]). We conclude that human CMN are associated with activated Wnt signaling.

A higher prevalence of CMN within some families suggests a germ-line predisposition to CMN ([@bib6]; [@bib18]; [@bib7]), and neurological phenotypic variability between patients with similar cutaneous phenotypes also supports a role for a modifying germline genotype. Accordingly, we performed whole-exome next-generation sequencing on DNA from peripheral white blood cells of 32 children with extensive CMN (phenotypic classification in [Supplementary Table S1 online](#sup1){ref-type="supplementary-material"}). In CMN syndrome, mutation of *NRAS* is a somatic event ([@bib21]). Therefore, in these blood samples, *NRAS* is wild type in all cases. Using the filters described in the [Supplementary Materials and Methods online](#sup1){ref-type="supplementary-material"} to identify rare variants in Wnt signaling pathway genes, 3,213,226 calls were reduced to 32 variants in 26 genes that occur with a prevalence \<0.5% in control population databases and to 34 variants in 26 genes at \<1% prevalence. After manually reviewing the BAM files, 20 variants in 32 patients were judged sufficiently convincing on all parameters to investigate further, and of these 19 were confirmed by Sanger sequencing. One was not confirmed, and one was not able to be confirmed because of lack of patient sample but was sufficiently convincing on next-generation sequencing to be included in the analyses. Genetic variation in *FZD1* was seen in six CMN patients and therefore considered a possible undescribed SNP (pending confirmation of its prevalence by direct screening of a large control population). These 19 variants seen in 14 CMN patients are listed in [Table 1](#tbl1){ref-type="table"}. This list includes variants in the *APC, APC2*, *FZD6*, *TCF3*, and *WNT16* genes that are absent from control population databases. Although functional characterization of each individual variant is beyond the scope of the current study, this analysis is supportive for a role for germ-line alterations of Wnt signaling, together with somatic activation of NRAS, in the development of extensive CMN.

Activation of Wnt signaling and NRAS recapitulates CMN syndrome in a mouse model
--------------------------------------------------------------------------------

On the basis of this finding, we asked whether combined activation of NRAS and Wnt signaling in the melanocytic lineage could drive formation of CMN syndrome in an animal model. We therefore generated mice with either activated NRAS (*Tyr-NRas*^*Q61K*^ ([@bib1]) or activated Wnt signaling alone (*Tyr-Cre Apc*^*fl.fl*^ ([@bib34])) or both activated NRAS and Wnt signaling (*Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ ([@bib27])), all under the control of the mouse *Tyr* promoter to restrict altered signaling largely to the melanocytic lineage ([@bib9]). These mice were then examined for features characteristic of CMN syndrome in humans, including skin hyperpigmentation and excessive infiltration of pigmented melanocytes into the leptomeninges and brain ([Supplementary Figure S1 online](#sup1){ref-type="supplementary-material"}). As reported previously, *Tyr-NRas*^*Q61K*^ mice exhibited an excess of melanocytes in the dermis and became hyperpigmented with melanin within a few days of birth, compared with either wild-type mice or *Tyr-Cre Apc*^*fl.fl*^ mice ([@bib1]; [@bib27]). Strikingly, activation of Wnt-signaling in *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice greatly exacerbated the NRas^Q61K^-induced proliferative expansion of melanocytes and skin melanization (([Supplementary Figure S2 online](#sup1){ref-type="supplementary-material"}) and previously quantitated in ([@bib27])), comparable to the cutaneous features of extensive CMN ([Supplementary Figure S1A online](#sup1){ref-type="supplementary-material"}). In addition, on post mortem, *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice, but neither *Tyr-Cre Apc*^*fl.fl*^ nor *Tyr-NRas*^*Q61K*^ mice, were found to have neurological features characteristic of human CMN syndrome, including hyperpigmented spines ([Figure 2a](#fig2){ref-type="fig"} and [Supplementary Figure S1B online](#sup1){ref-type="supplementary-material"}) and the pathognomonic leptomeningeal melanosis around the spinal cord ([Figure 2b and c](#fig2){ref-type="fig"}). In the head, the mice showed melanosis and thickening of the leptomeninges, as well as melanosis in olfactory bulbs and nasal turbinates ([Figure 2d](#fig2){ref-type="fig"}). Invasion of melanin-producing cells around the spinal cord and into the brain was also observed by MRI ([Figure 2e and f](#fig2){ref-type="fig"} and [Supplementary Figure S1C, S1D](#sup1){ref-type="supplementary-material"} and [Supplementary Video S1 online](#sup1){ref-type="supplementary-material"}), highly reminiscent of the malignant progression seen in patients with CMN complicated by melanoma ([@bib31]; [@bib19]). The abnormal infiltrating pigment-producing cells in the mice were confirmed as melanocytes based on morphology, as well as expression of the neural crest cell marker S100 ([Supplementary Figure S3 online](#sup1){ref-type="supplementary-material"}).

Features of CMN syndrome are blocked through post-natal MEK inhibition
----------------------------------------------------------------------

As proliferative expansion of the melanocyte population in the *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice was dependent on dual activation of NRAS and Wnt signaling, we reasoned that inhibition of NRAS signaling alone should be sufficient to inhibit proliferation of these cells. To test this *in vitro*, we prepared cutaneous melanocytes from *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice. These genetically altered cells were highly pigmented and showed a dendritic morphology, characteristic of melanocytes ([Figure 3a](#fig3){ref-type="fig"}). To test the influence of reducing activity of the MAPK/ERK pathway, we treated *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse melanocytes *in vitro* with the allosteric MEK inhibitor, AZD6244 (selumetinib, ARRY-142886; [@bib43]). Upon MEK inhibition, proliferation was significantly reduced, as measured by a decrease in EdU incorporation and suppression of cyclin A expression ([Figure 3b--d](#fig3){ref-type="fig"}).

A massive expansion of melanocytes in the skin of *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice occurs predominantly within the first 2 weeks of life ([@bib27]). Therefore, we reasoned that treatment of such neonatal mice with a MEK inhibitor over the first 2 weeks of life could potentially decrease melanocytic proliferation and suppress features of CMN syndrome. Mice were treated three times weekly by intraperitoneal injection with AZD6244 or DMSO vehicle for 2 weeks after birth ([Figure 4a](#fig4){ref-type="fig"}). PhosphoERK staining in the liver was markedly decreased, confirming that this regimen effectively inhibited MEK--ERK signaling in the mice ([Supplementary Figure S4 online](#sup1){ref-type="supplementary-material"}). Treatment with AZD6244 greatly reduced the population of melanocytes in the skin dermis ([Figure 4b](#fig4){ref-type="fig"}) compared to vehicle and, crucially, significantly decreased numbers of melanocytes in the CNS ([Figure 4c and d](#fig4){ref-type="fig"}). Indicative of at least partial sustained benefit from drug treatment, acute post-natal treatment with AZD6244 over 2 weeks, followed by withdrawal from therapy, resulted in a significant decrease in pigmentation within the CNS 4 weeks after the end of drug treatment ([Figure 5](#fig5){ref-type="fig"}).

Discussion
==========

Here we present several lines of evidence to indicate that, in at least a subset of cases of human CMN syndrome, the phenotype is likely to be driven by concerted aberration of NRAS and Wnt signaling. First, by whole-exome sequencing we identified a number of sequence variants in genes of the Wnt signaling pathway in DNA of peripheral white blood cells. Several of these variants are to our knowledge previously unreported, and those described are detected only at extremely low frequency in published databases. All are predicted to impair the function of the encoded protein, where *in silico* prediction is possible. Given the complexity of the Wnt signaling pathway, comprising positive and negative regulators and antagonistic interactions between canonical Wnt/β-catenin signaling and the non-canonical Wnt pathway ([@bib25]), it is difficult to confidently ascertain whether these variants activate or inhibit Wnt/β-catenin signaling, without extensive additional functional studies. At this time, these sequence variants are good candidates for heritable, germ-line variants that alter activity of the Wnt signaling pathway, which we postulate may have a synergistic effect in the presence of a somatic *NRAS* mutation. Second, we observed that human CMN exhibit markers of activated Wnt signaling, suggesting that the effect of activated Wnt is not only important in the congenital development of the disease but may be involved in the post-natal persistence of the nevus. Third, in a mouse model that to our knowledge is previously unreported, we showed that melanocyte-specific activated NRAS^Q61K^ and activated Wnt signaling, through inactivation of APC, cooperate to generate features of CMN syndrome, most notably a massive excess of melanocytes in the skin and infiltration of melanocytes into the leptomeninges and CNS. Finally, post-natal systemic treatment with a MEK inhibitor, an inhibitor of NRAS signaling, reversed both the cutaneous and neurological features of this mouse model.

Previous reports have described other genetically modified mice exhibiting phenotypes that partially resemble CMN syndrome. Merlino and coworkers showed that constitutive expression of Scatter factor/hepatocyte growth factor under control of the mouse metallothionein I promoter induced melanosis in the CNS and hyperpigmentation in the skin ([@bib40]). Although we cannot exclude a role for Scatter factor/hepatocyte growth factor signaling in CMN syndrome, this model does not recapitulate the most common hallmark of human CMN syndrome, *NRAS* codon 61 mutation ([@bib21]). Several groups have previously reported hyperpigmentation in the skin of mice expressing NRas^Q61K^ in the melanocyte lineage ([@bib1]; [@bib8]; [@bib33]). However, consistent with our observations, none of these groups reported any neurological involvement. One of these studies found that a stabilized β-catenin allele cooperated with NRas^Q61K^ to promote melanoma ([@bib8]). However, these melanomas were proposed to arise from the hair follicle bulb or the bulge region in the skin. As discussed previously ([@bib27]), we have not observed any frank melanoma in *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice, likely because the behavioral and neurological abnormalities associated with CNS infiltration, themselves characteristic of CMN syndrome ([@bib2]; [@bib18]; [@bib19]), preclude keeping any live mice beyond 4 months for ethical reasons.

Marais and coworkers reported in a murine model that expression of NRAS^G12D^ in the melanocyte lineage induced melanocyte proliferation and congenital melanocytic skin lesions and also primary melanoma of the CNS of variable latency but high penetrance ([@bib28]). Human CMN syndrome, however, is typically characterized by mutation of *NRAS* at codon 61, not codon 12 ([@bib21]), although a uncommon variant of CMN is rarely associated with codon 13 mutations ([@bib20]), with a single case report of brain involvement in a patient with p.G13R ([@bib35]). In addition, the most common congenital CNS finding is melanosis in the parenchyma or the leptomeniges, with intracerebral primary melanoma being a more rare and acquired phenomenon. Thus, the *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^mice reported here appear, to date, to be the best combined genetic and phenotypic recapitulation of human CMN syndrome.

The idea that CMN syndrome results from activated NRAS and Wnt signaling extends the model previously proposed for human acquired melanocytic nevi. Specifically, their formation is thought to depend on activated NRAS or BRAF signaling, due to oncogenic mutation of *NRAS* or *BRAF* ([@bib26]; [@bib29]), and also depends on input from the Wnt signaling pathway ([@bib27]). Normal human melanocytes are exposed to activated Wnt signaling as they migrate from the neural crest to the epidermis ([@bib13]; [@bib10]; [@bib11]), and this might be the source of Wnt signaling for benign nevogenesis ([@bib27]), either congenital *in utero* or acquired, which typically occurs in young children ([@bib3]; [@bib44]). In some cases of CMN syndrome, we propose that somatic *NRAS* mutation cooperates with a higher level of sustained Wnt signaling resulting from germ-line genetic variants or other activators of the Wnt pathway to drive a much more severe melanocytic expansion. This germ-line modifier could provide a possible explanation for the unexplained observation of the presence or absence of neurological involvement in unrelated CMN syndrome individuals with the same cutaneous phenotype----a clinical problem that leads to all children with multiple CMN having MRI screening of the CNS in the first few months of life ([@bib41]). Additional studies are required to confirm the functional significance of these variants in the pathogenesis of CMN syndrome.

Alterations of Wnt signaling in pediatric pathologies are not exclusive to CMN syndrome. For instance, more than half of all pediatric Wilms\' tumor (the fourth most common childhood malignancy) have been reported to show Wnt activation ([@bib37]). In the mouse, activation of KRAS and stabilization of β-catenin, specifically in the developing kidney, cause metastatic renal epithelial tumors to develop that mimic the epithelial component of Wilms\' tumor ([@bib5]). As in CMN syndrome, the molecular basis of Wnt signaling activation driving this disease is often unclear ([@bib37]). With a greater understanding of the cross-talk between *RAS* and Wnt signaling in benign and advanced disease, we may better decipher the inner workings of multiple childhood malignancies.

An understanding of the genetic basis of CMN syndrome is a likely first step to therapeutic interventions. On the basis of our previous finding that CMN syndrome is caused by somatic *NRAS* mutation ([@bib21]), a recent report administered an oral MEK inhibitor to a 13-year-old boy with CMN syndrome in the very advanced stages of leptomeningeal melanoma ([@bib23]). Despite biomarker responses to the drug, the child passed away within days, as would be expected from the natural history of this malignancy at this stage. As onset of melanoma in CMN is known to require further key mutations affecting proliferative pathways ([@bib21]), intervention before progression to malignancy is likely to be the key to success. In support of further testing of this approach, here we report that acute post-natal inhibition of MEK--ERK signaling downstream of NRAS^Q61K^ does substantially rescue the key features of CMN syndrome in this mouse model, specifically the massive expansion of melanocytes in the skin, brain, and leptomeninges. These results suggest that MEK inhibitors, currently Food and Drug Administration--approved or being trialed for use in melanoma ([@bib38]), might also benefit patients with CMN syndrome. Importantly, although the cure of advanced melanoma through application of targeted therapies, such as MEK and BRAFV600E inhibitors ([@bib36]), has ultimately been frustrated often by acquisition of drug resistance, conceivably this might not be a confounding factor in CMN syndrome with its many fewer genetic alterations.

Materials and Methods
=====================

Additional details of Materials and Methods are available in [Supplementary Materials and Methods online](#sup1){ref-type="supplementary-material"}.

Human tissues
-------------

Congenital melanocytic nevi were obtained under an Institutional Review Board approved protocol by a board-certified dermatopathologist (HWM) from Fox Chase Cancer Center, Philadelphia. These tissues were fixed in 10% (vol/vol) buffered formalin for 1**--**3 days and embedded in paraffin, following routine histology procedure.

For whole-exome sequencing, peripheral blood leukocyte DNA was extracted from samples from 32 children with CMN attending a specialist clinic at Great Ormond St Hospital, London. Written consent was obtained in all cases, and the study was approved by the Great Ormond Street Hospital/UCL Institute of Child Health Research Ethics Committee. Detailed phenotyping of the cutaneous and neurological signs of the participants is shown in [Supplementary Table S1 online](#sup1){ref-type="supplementary-material"}, demonstrating that this group is at the severe end of the phenotypic spectrum of individuals with CMN.

Immunoblotting
--------------

Cells were lysed in 1 × Laemmeli sample buffer, and 30--50 μg of protein was resolved by SDS-polyacrylamide gel electrophoresis followed by transfer onto PVDF membrane and probing with antibodies. Antibodies used include the following: anti-cyclin A (SC-754, Santa Cruz Biotechnology, Dallas, TX), anti-β-actin (A1978, Sigma, St. Louis, MO), p44/42 MAPK (Erk1/2, 4695, Cell Signaling, Danvers, MA) and phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204, 9101, Cell Signaling), anti-rabbit IgG, horseradish peroxidase-linked (NA934, GE Healthcare, Fairfield, CT), and anti-mouse IgG, horseradish peroxidase-linked (P0447, Dako, Carpinteria, CA).

Cell proliferation assays, immunofluorescence
---------------------------------------------

The Click-iT EdU Alexa Fluor 594 Imaging Kit (C10339, Life Technologies, Carlsbad, CA) was used according to the manufacturer\'s instructions to monitor cellular proliferation.

Immunohistochemistry
--------------------

Briefly, formalin fixed, paraffin embedded sections were deparaffinised, rehydrated, blocked for endogenous peroxidases, and underwent antigen retrieval according to antibody specifications. Tissues were incubated overnight with the following primary antibodies: Anti-human melan-a clone A103 (Dako, M7196), S100 (Dako, Z0311), β-catenin (610154, BD Transduction Laboratories, San Jose, CA), CyclinD1 clone EP12 (Dako, M3642), c-myc clone 9E10 (Santa Cruz Biotechnology, sc-40), p44/42 MAPK (Erk1/2; Cell Signaling, 4695) and phospho-p44/42 MAPK (Erk1/2, Thr202/Tyr204, Cell Signaling, 9101), mouse IgG (I-2000, Vector, Burlingame, CA), and rabbit IgG (Vector, I-1000). Secondary antibodies used for DAB-based IHC were either EnVision+ System- horseradish peroxidase Labeled Polymer Anti-mouse (Dako, K4001) or EnVision+ System- horseradish peroxidase Labeled Polymer Anti-rabbit (Dako, K4003) based on primary antibody host species. Peroxidase activity was revealed using DAB (Dako, K3468). Samples were then counterstained with haematoxylin, dehydrated, and coverslipped.

Genetically modified mice
-------------------------

*Tyr-NRas*^*Q61K*^ mice and *Apc*^*fl.fl*^ mice were mated to *Tyr-Cre* mice ([@bib34]; [@bib9]; [@bib1]). Progenies from these crosses were then interbred to obtain *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ and were maintained on a C57BL6 background. Mice were kept in conventional animal facilities, monitored frequently, and experiments were carried out in compliance with UK Home Office guidelines at the Beatson Institute for Cancer Research mouse facility (Home Office PCD 60/2,607) under project license 60/4,079. Mice were genotyped by Transnetyx. Mice were first treated at their day of birth or at 1 day of age with AZD6244 (10 mg kg^−1^) or DMSO vehicle via intraperitoneal injection and then three times per week for 2 weeks. Mice were euthanized following a Schedule 1 method, and tissues were collected for histological analyses.

Whole-exome sequencing
----------------------

Whole-exome sequencing was performed in two batches of 23 and 10 samples. For the first batch, a total of 3 μg of DNA was used to prepare a DNA library using Covaris DNA sonication and NEB NEBNext DNA Sample Prep Reagent Set 1 (E6000S, New England Biolabs, Ipswich, MA). DNA fragments containing adaptors were enriched by PCR (four cycles). Samples were processed using SureSelect target Enrichment System for Illumina Paired-End Sequencing Library (Protocol version 2.0.1 May 2010). Purified libraries were checked for quality throughout the process and quantified using an Agilent (Santa Clara, CA) 2,100 Bioanalyser. Samples were sequenced using Illumina (San Diego, CA) Solexa chemistry on a Genome Analyzer IIx. Illumina 76 bp paired end kits were used according to the manufacturer\'s protocol. For the second batch, paired-end library preparation was by Illumina Nextera Rapid Capture Enrichment (protocol June 2013) using 50 ng DNA and sequenced on an Illumina HiSeq 2,000. Sequences were analyzed as described in [Supplementary Materials and Methods online](#sup1){ref-type="supplementary-material"}.
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![**Human congenital melanocytic nevi harbor activated Wnt signaling.** Serial sections of a CMN stained for melan A, β-catenin, cyclin D1, and c-myc. Images are representative of at least four congenital human nevi (Scale bar=25 μm).](jid2015114f1){#fig1}

![**A mouse model harboring activated RAS and Wnt signaling recapitulates human CMN syndrome.** (**a**) Representative images of blackened spine and head in 2-week-old *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice (right (representative of \>60 mice)) compared with wild-type mice (left). *Tyr-Cre Apc*^*fl.fl*^ and *Tyr-NRas*^*Q61K*^ were indistinguishable from wild-type mice in these respects (not shown). (**b**) Transverse H+E section showing melanocytic infiltration (melanin) into leptomeninges of the spine of *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse (right) compared with wild-type mouse (left). (**c**) Longitudinal H+E section showing melanocytic infiltration (melanin) into leptomeninges of the brain of *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse (bottom) compared with wild-type mouse (top). (**d**) Melanocytic infiltration of cartilage and the olfactory system of *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse. (**e**) Longitudinal MRI showing melanocytic invasion (white) into the head in *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse (bottom) compared with wild-type mouse (top). (**f**) Longitudinal MRI showing melanocytic invasion (white) around spine in *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse (right) compared with wild-type mouse (left). Blue arrows indicate melanocytic infiltration. APC, adenomatous polyposis coli; B, Brain; CMN, congenital melanocytic nevus; MRI, magnetic resonance imaging; OB, Olfactory Bulb; SC, spinal cord; Sk, Skull; T, Turbinates; VB, vertebral body; WT, wild type.](jid2015114f2){#fig2}

![***Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse melanocytes are sensitive to MEK inhibition *in vitro*.** (**a**) Phase contrast image of dendritic, pigmented melanocytes isolated from the skin of *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mouse (Scale bar = 25 μm). (**b**) MEK inhibitor, AZD6244, downregulates phosphoERK and cyclin A expression. Cells were treated with DMSO vehicle or AZD6244, as indicated. (**c**) EdU labeling and DAPI stain of nuclei from **b** (Scale bar=25 μm). (**d**) Quantitation of EdU labeling from (**c**). Results from three experiments, each scoring \>100 DAPI-stained nuclei. Linear mixed-effects model was performed to compare the difference in percent EdU positive.](jid2015114f3){#fig3}

![**Inhibition of MEK suppresses features of CMN syndrome *in vivo*.** (**a**) Newborn *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice were repeatedly injected IP (three times per week for 2 weeks) with vehicle or AZD6244. Two weeks later, mice were euthanized and tissues were harvested and processed. (**b**) S100 stained skin sections from *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice treated with vehicle (left) compared with AZD6244 treatment (right). **(c)** Representative images showing dorsal view of *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice treated with vehicle (left) or AZD6244 (right), after removal of the skin. (**d**) (Left) Quantitation of percent melanization in (**c**) along length of mouse from anterior of brain (0.0) to posterior of spine (1.0); (right) magnified portion of boxed region of left. Seven mice of each group with roughly ten analyses per mouse were quantitated. Linear mixed-effects model was fitted to compare the percent area between AZD6244-treated and vehicle groups. CMN, congenital melanocytic nevus; CNS, central nervous system.](jid2015114f4){#fig4}

![**Acute MEK inhibition therapy has prolonged effects when given post-natally.** (**a**) Representative images showing dorsal view of 6-week-old *Tyr-Cre Apc*^*fl.fl*^*/Tyr-NRas*^*Q61K*^ mice either not treated (NT, left) or treated with AZD6244 for 2 weeks followed by 4 weeks off drug (right), after removal of the skin. (**b**) Quantitation of percent melanization in **a** along length of mouse from anterior of brain (0.0) to posterior of spine (1.0); analysis performed same way as [Figure 4d](#fig4){ref-type="fig"}. Three mice of each group with roughly 17 analyses per mouse were quantitated. Linear mixed-effects model was fitted to compare percent area between AZD6244-treated and -untreated groups. CNS, central nervous system.](jid2015114f5){#fig5}

###### Details of 19 rare germline variants found in 14 CMN patients on whole-exome sequencing

  **Gene symbol**   **Position(Hg19)**   **Reference allele/Sample allele**                          **Protein variants**      **Translation impact**   **Predicted functional impact: SIFT function prediction (score), PolyPhen-2 function prediction**   **Conservation phyloP p-value** (<http://compgen.bscb.cornell.edu/phast/help-pages/phyloP.txt>)   **dbSNP ID** (<http://www.ncbi.nlm.nih.gov/SNP/>)    **Frequency in control population: 1,000 Genomes/CG public genomes/NHLBI ESP**
  ----------------- -------------------- ----------------------------------------------------------- ------------------------- ------------------------ --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------------
  *APC*             5:112176056          C/T                                                         p.R1571C; p.R1589C        Missense                 Damaging (0.05, possibly damaging                                                                   0.005152                                                                                                                                                                                 ---/---/0
  *APC2*            19:1453017           C/T                                                         p.A6V                     Missense                 Damaging (0.05), probably damaging                                                                  1.83E--05                                                                                         rs200897976                                                                          0.19/---/0.02
  *APC2*            19:1465820           5′-GGCCAAGGCCAAGGCCAAG-3′/5′-GGCCAAGGCCAAGGCCAAGGCCAAG-3′   p.K846_L847insAK          In-frame                                                                                                                                                                                                                                                                                                              ---/---/0
  *EP300*           22:41569633          A/G                                                         p.K1542E                  Missense                 ---, Possibly damaging                                                                              3.52E--04                                                                                         rs374162524                                                                           ---/---/0.01
  *FZD1*            7:90894459           ACC/ACCACC                                                  p.P89_P90insP             In-frame                                                                                                                                                                                                                                                                                                              ---/---/0
  *FZD6*            8:104341919          AT/---                                                      p.C527\* p.C495\*         Frameshift                                                                                                                                                                                                                                                                                                            ---/---/0
  *HNF1A*           12:121426790         G/A                                                         p.A161T                   Missense                 Damaging (0.03), probably damaging                                                                  1.32E--04                                                                                         rs201095611                                                                           ---/---/0.01
  *LRP1*            12:57577915          C/T                                                         p.R1993W                  Missense                 Damaging (0), probably damaging                                                                                                                                                                       rs141826184                                                                          0.05/---/0.22
  *LRP1*            12:57602881          A/T                                                         p.Y4054F                  Missense                 Damaging (0.02), probably damaging                                                                  2.47E--05                                                                                         rs79435985                                                                             0.96/---/0
  *MAP4K1*          19:39108034          G/A                                                         p.R70W                    Missense                 Damaging (0), probably damaging                                                                                                                                                                       rs35079766                                                                           0.11/---/0.11
  *PPP2R1B*         11:111608216         T/A                                                         p.N623Y; p.N559Y          Missense                 Damaging (0.01), possibly damaging                                                                                                                                                                    rs61756429                                                                           0.35/0.92/0.76
  *PPP2R1B*         11:111631738         AC/---                                                      p.V115fs\*3; p.V51fs\*3   Frameshift                                                                                                                   2.11E--05                                                                                                                                                                               ---/---/0.06
  *PPP2R3B*         X:308383             C/T                                                         p.A186T                   Missense                 Damaging (0.04), possibly damaging                                                                  7.33E--05                                                                                                                                                                               ---/---/0.05
  *RARB*            3:25636151           C/T                                                         p.R266C; p.R378C          Missense                 Damaging (0), probably damaging                                                                     1.03E--06                                                                                                                                                                                ---/---/0
  *SOX8*            16:1034833           A/T                                                         p.N263I                   Missense                 Damaging (0.01), possibly damaging                                                                  1.88E--03                                                                                         rs201359112                                                                            ---/---/0
  *TCF3*            19:1621908           GAGGAG/GAG                                                  p.S295del                 In-frame                                                                                                                     1.07E--03                                                                                                                                                                                ---/---/0
  *TCF7*            5:133480486          A/G                                                                                                                                                                                                                1.31E--05                                                                                         rs201733691                                                                           ---/---/0.04
  *WNT16*           7:120965470          ---/CCA                                                     p.M1fs\*141               Frameshift                                                                                                                                                                                                                                                                                                            ---/---/0
  *WNT9B*           17:44950095          G/A                                                         p.R97H                    Missense                 Damaging (0), probably damaging                                                                     1.93E--06                                                                                         rs201223229                                                                            0.06/---/0

Abbreviation: APC, adenomatous polyposis coli.

Whole-exome sequencing was performed on peripheral blood leukocyte DNA from children with CMN. Data were analyzed to identify rare pathogenic variants (\<1% of the population in published control data sets) in genes in the APC/Wnt-signaling pathway.

[^1]: Current address: Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
